CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway

By S. Ma, Tk Lee, B. Zheng, Kw Chan, X. Guan. Oncogene, 2008

804 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/7c4200886eb193e80b2244261538e96eac4dd7cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Subash C. Gupta
2. Bharat B. Aggarwal
3. M. Wicha
4. M. Chaturvedi
5. Simone Reuter
6. K. Harikumar

In Oncology

1. H. Korkaya
2. Subash C. Gupta
3. Bharat B. Aggarwal
4. M. Wicha
5. Simone Reuter

Citations in the corpus

• HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion (2008, background): “, 2007) and in mediating treatment resistance (Ma et al., 2007; Saal et al., 2007).”
• Oxidative stress, inflammation, and cancer: how are they linked? (2010, background): “Additionally, two studies showed that CD133+ CSCs conferred chemoresistance to cisplatin and doxorubicin (known ROS generators) in ovarian cancer cells [296] and hepatocellular carcinoma [297], respectively.”